<unk>  is indicated as a CD38-directed cytolytic antibody. By inhibiting the enzymatic activity of CD38. The binding of<unk>  to CD38 on multiple myeloma (MM) cells leads to a trigger to several mechanisms leading to direct apoptosis of target cancer cells. The triggered pathways are the caspase-dependent apoptotic and the lysosome-mediated cell death pathway in MM cells. It is used in a combination with dexamethasone and pomalidomide. The drug is thus to treat patients with multiple myeloma. Restrictions for the use of<unk>  is that the patients have to be adults who have at least received two previous treatments with lenalidomide and a proteasome inhibitor.<unk>  is currently also being tested in a Phase II trial as a monotherapy against refractory/recurrent systemic light-chain amyloidosis.
Isatuximab
Siltuximab
Margetuximab
Dinutuximab
Loncastuximab tesirine
Alirocumab
Daratumumab
Blinatumomab